Letrozole increases ovarian growth and CYP17A1 gene expression
Friday, March 1, 2013
Letrozole increases ovarian size and androgen production and upregulates Cyp17a1 messenger RNA expression in the rat ovary.
Letrozole increases ovarian size and androgen production and upregulates Cyp17a1 messenger RNA expression in the rat ovary.
A review is presented of the role of aromatase in the pathogenesis of endometriosis, discuss the pharmacology of aromatase inhibitors, and examine clinical applications of aromatase inhibitors for endometriosis treatment.
Studies suggest that in the short term, an aromatase inhibitor plus gonadotropin protocol is effective for safely inducing controlled ovarian hyperstimulation in women with breast cancer for fertility preservation.
Higher FSH start dose does not improve cycle outcomes in women with breast cancer undergoing fertility preservation with letrozole for embryo cryopreservation.
Lower estradiol production and P450 aromatase messenger RNA expression of cultured granulosa cells were found in women with endometriosis, but letrozole in the conditioned media further reduced these parameters.
Therapy with 2.5 mg letrozole or 1 mg anastrazole daily, in cases of infertile men with low T/E2 ratios, leads to a significant increase of T/E2 ratio, ejaculate volume, sperm motility, and total motile sperm count.
The optimal size of the leading follicle in cycles with clomiphene citrate and letrozole is in the range of 23–28 mm and is closely related to the endometrial thickness.
This report describes the peripheral levels of inhibin B and antimullerian hormone in boys during peripuberty and in patients with congenital hypogonadotropic hypogonadism.